Intravesical Therapy for Superficial Bladder Cancer
نویسندگان
چکیده
Transitional cell carcinoma of the bladder remains a significant health problem in the United States. Approximately 54,400 new cases of transitional cell carcinoma were reported in the United States in 1999, and an estimated 12,500 deaths were attributed to this cancer.[1] These statistics have remained relatively unchanged over the last several decades despite improvements in both diagnostic instrumentation and therapeutic intervention, as well as greater awareness of cigarette smoking and occupational chemical exposure as important risk factors.
منابع مشابه
Contemporary management of superficial bladder cancer.
BACKGROUND Bladder cancer is the second most common urologic malignancy after prostate cancer. Superficial bladder cancer presents as a heterogeneous group of tumors with variable biological potential. A significant percentage of patients diagnosed with superficial cancer will have multiple recurrences, and some will progress to invasive disease. METHODS Patients are stratified into low- or h...
متن کاملAn unusual cause of retention of urine after intravesical Bacillus Calmette-Guérin therapy for superficial bladder cancer.
We report an unusual complication of intravesical Bacillus Calmette-Guérin therapy for superficial bladder cancer, namely, retention of urine secondary to prostatic Bacillus Calmette-Guérin infection and abscess. A summary of the literature together with a review of its management is discussed.
متن کاملBCG Prevention of the Recurrence of Bladder Cancers Prevention of the Recurrence of Superficial Bladder Cancers: Intravesical Instillation of Bacillus Calmette-guerin Versus Bacillus Calmette-guerin Plus Epirubicin
Purpose The short-term effects of intravesical chemoimmunotherapy with epirubicin and Bacillus CalmetteGuerin (BCG) administered repeatedlly for prophylaxis of recurrence of superficial bladder cancer (pTa, pT1) were investigated in 22 patients with a median of 70 years between March, 1995 and February, 1999, and were compared with those of BCG monotherapy in 50 patients between March, 1995 and...
متن کاملTherapies in bladder cancer: intravesical mitomycin-C
The use of intravesical therapy for the treatment of superficial bladder cancer aims to reduce morbidity and mortality by eradicating existing disease, preventing tumor recurrence and attempting to halt tumor progression. Mitomycin-C is a commonly used intravesical treatment option for superficial bladder cancer and was used for the first time by Shida and colleagues in 1967 [1]. It is an antit...
متن کاملIntravesical therapy in superficial bladder cancer.
OBJECTIVE To identify the appropriate characteristics of superficial bladder cancer that allow the physician to predict tumor behavior. METHODS We analyzed 1,745 patients with primary superficial bladder cancer with regard to disease and patient characteristics. RESULTS With the characteristics we found, the population can be described and prognostic factors can be found. Moreover, with the...
متن کاملPeritoneal tuberculosis presenting as recurrent peritonitis secondary to treatment with intravesical Bacillus Calmette-Guérin in a patient receiving peritoneal dialysis
Intravesical Bacillus Calmette-Guérin (BCG) is an established treatment for high-risk superficial bladder cancer [Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors.1976. J Urol 2002; 167: 891-893, Lamm DL, van der Meijden APM, Morales A et al. Incidence and treatment of complications of Bacillus Calmette-Guérin intravesical th...
متن کامل